Generation of Recombinant Human Parainfluenza Virus Type 1 Vaccine Candidates by Importation of Temperature-Sensitive and Attenuating Mutations from Heterologous Paramyxoviruses

Journal of Virology

Volumn 78, Issue 4, 2004, Pages 2017-2028

  Newman, Jason T ^a   Riggs, Jeffrey M ^a   Surman, Sonja R ^a   McAuliffe, Josephine M ^a   Mulaikal, Teresa A ^a   Collins, Peter L ^a   Murphy, Brian R ^a   Skiadopoulos, Mario H ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HPIV1 VACCINE; HPIV3 VACCINE; L POLYMERASE; LIVE VACCINE; MUTANT PROTEIN; PROTEIN C; PROTEIN CPTS530; PROTEIN HPIV3CP45; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN; VIRUS PROTEIN F; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; BINDING SITE; GENE MUTATION; HAMSTER; HUMAN; INFANT DISEASE; LOWER RESPIRATORY TRACT; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAINFLUENZA VIRUS 1; PARAMYXOVIRUS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; TEMPERATURE SENSITIVE MUTANT; TEMPERATURE SENSITIVITY; VACCINATION; VIRUS ATTENUATION; VIRUS MUTATION;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CRICETINAE; HUMANS; MESOCRICETUS; MOLECULAR SEQUENCE DATA; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 3, HUMAN; PARAMYXOVIRIDAE; POINT MUTATION; RESPIRATORY SYNCYTIAL VIRUSES; RESPIROVIRUS INFECTIONS; TEMPERATURE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 0842282831     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.4.2017-2028.2004     Document Type: Article

References (54)

1. Atmar, R. L., E. Guy, K. K. Guntupalli, J. L. Zimmerman, V. D. Bandi, B. D. Baxter, and S. B. Greenberg. 1998. Respiratory tract viral infections in inner-city asthmatic adults. Arch. Intern. Med. 158:2453-2459.
2. Belshe, R. B., and F. K. Hissom. 1982. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol. 10:235-242.
3. Chanock, R. M., B. R. Murphy, and P. L. Collins. 2001. Parainfluenza viruses, p. 1341-1379. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, Pa.
4. Collins, P. L., and B. R. Murphy. 2002. Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296:204-211.
5. Collins, P. L., S. S. Whitehead, A. Bukreyev, R. Fearns, M. N. Teng, K. Juhasz, R. M. Chanock, and B. R. Murphy. 1999. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. 54:423-451.
6. Cortez, K. J., D. D. Erdman, T. C. Peret, V. J. Gill, R. Childs, A. J. Barrett, and J. E. Bennett. 2001. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J. Infect. Dis. 184:1093-1097.
7. Counihan, M. E., D. K. Shay, R. C. Holman, S. A. Lowther, and L. J. Anderson. 2001. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr. Infect. Dis. J. 20:646-653.
8. Crowe, J. E. 2001. Respiratory syncytial virus vaccine development. Vaccine 20(Suppl. 1):S32-S37.
9. Crowe, J. E., Jr., P. T. Bui, G. R. Siber, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847-855.
10. Crowe, J. E., Jr., P. L. Collins, R. M. Chanock, and B. R. Murphy. 1997. Vaccines against respiratory syncytial virus and parainfluenza virus type 3, p. 711-725. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
11. Durbin, A. P., S. L. Hall, J. W. Siew, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1997. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235:323-332.
12. Durbin, A. P., J. M. McAuliffe, P. L. Collins, and B. R. Murphy. 1999. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261:319-330.
13. Durbin, A. P., M. H. Skiadopoulos, J. M. McAuliffe, J. M. Riggs, S. R. Surman, P. L. Collins, and B. R. Murphy. 2000. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J. Virol. 74:6821-6831.
14. Fiore, A. E., C. Iverson, T. Messmer, D. Erdman, S. M. Lett, D. F. Talkington, L. J. Anderson, B. Fields, G. M. Carlone, R. F. Breiman, and M. S. Cetron. 1998. Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J. Am. Geriatr. Soc. 46:1112-1117.
15. Garcia-Sastre, A. 2001. Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 279:375-384.
16. Garcin, D., M. Itoh, and D. Kolakofsky. 1997. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology 238:424-431.
17. Garcin, D., J. B. Marq, S. Goodbourn, and D. Kolakofsky. 2003. The amino-terminal extensions of the longer Sendai virus C proteins modulate pY701-Stat1 and bulk Stat1 levels independently of interferon signaling. J. Virol. 77:2321-2329.
18. Garcin, D., J. B. Marq, L. Strahle, P. le Mercier, and D. Kolakofsky. 2002. All four Sendai virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology 295:256-265.
19. Gotoh, B., T. Komatsu, K. Takeuchi, and J. Yokoo. 2001. Paramyxovirus accessory proteins as interferon antagonists. Microbiol. Immunol. 45:787-800.
20. Gotoh, B., T. Komatsu, K. Takeuchi, and J. Yokoo. 2002. Paramyxovirus strategies for evading the interferon response. Rev. Med. Virol. 12:337-357.
21. Hall, S. L., C. M. Sarris, E. L. Tierney, W. T. London, and B. R. Murphy. 1993. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees. J. Infect. Dis. 167:958-962.
22. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184.
23. Heikkinen, T., M. Thint, and T. Chonmaitree. 1999. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 340:260-264.
24. Henderson, F. W., A. M. Collier, M. A. Sanyal, J. M. Watkins, D. L. Fairclough, W. A. Clyde, Jr., and F. W. Denny. 1982. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N. Engl. J. Med. 306:1377-1383.
25. Itoh, M., Y. Isegawa, H. Hotta, and M. Homma. 1997. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J. Gen. Virol. 78:3207-3215.
26. Jokinen, C., L. Heiskanen, H. Juvonen, S. Kallinen, M. Kleemola, M. Koskela, M. Leinonen, P. R. Ronnberg, P. Saikku, M. Sten, A. Tarkiainen, H. Tukiainen, K. Pyorala, and P. H. Makela. 2001. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin. Infect. Dis. 32:1141-1154.
27. Juhasz, K., B. R. Murphy, and P. L. Collins. 1999. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. J. Virol. 73:5176-5180.
28. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, J. E. Crowe, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819.
29. Karron, R. A., R. B. Belshe, P. F. Wright, B. Thumar, B. Burns, F. Newman, J. C. Cannon, J. Thompson, T. Tsai, M. Paschalis, S. L. Wu, Y. Mitcho, J. Hackell, B. R. Murphy, and J. M. Tatem. 2003. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22:394-405.
30. Karron, R. A., P. F. Wright, F. K. Newman, M. Makhene, J. Thompson, R. Samorodin, M. H. Wilson, E. L. Anderson, M. L. Clements, B. R. Murphy, and R. B. Belshe. 1995. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1445-1450.
31. Lewis, V. A., R. Champlin, J. Englund, R. Couch, J. M. Goodrich, K. Rolston, D. Przepiorka, N. Q. Mirza, H. M. Yousuf, M. Luna, G. P. Bodey, and E. Whimbey. 1996. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin. Infect. Dis. 23:1033-1037.
32. Marx, A., H. E. Gary, Jr., B. J. Marston, D. D. Erdman, R. F. Breiman, T. J. Torok, J. F. Plouffe, T. M. File, Jr., and L. J. Anderson. 1999. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin. Infect. Dis. 29:134-140.
33. Marx, A., T. J. Torok, R. C. Holman, M. J. Clarke, and L. J. Anderson. 1997. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176:1423-1427.
34. Matsuoka, Y., J. Curran, T. Pelet, D. Kolakofsky, R. Ray, and R. W. Compans. 1991. The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. J. Virol. 65:3406-3410.
35. Moeller, K., I. Duffy, P. Duprex, B. Rima, R. Beschorner, S. Fauser, R. Meyermann, S. Niewiesk, V. ter Meulen, and J. Schneider-Schaulies. 2001. Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J. Virol. 75:7612-7620.
36. Murphy, B. R., and P. L. Collins. 2002. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Investig. 110:21-27.
37. Murphy, B. R., E. J. Park, P. Gottlieb, and K. Subbarao. 1997. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 15:1372-1378.
38. Murphy, B. R., D. D. Richman, E. G. Chalhub, C. P. Uhlendorf, S. Baron, and R. M. Chanock. 1975. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect. Immun. 12:62-68.
39. Newman, J. T., S. R. Surman, J. M. Riggs, C. T. Hansen, P. L. Collins, B. R. Murphy, and M. H. Skiadopoulos. 2002. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24:77-92.
40. Power, U. F., K. W. Ryan, and A. Portner. 1992. The P genes of human parainfluenza virus type 1 clinical isolates are polycistronic and microheterogeneous. Virology 189:340-343.
41. Reed, G., P. H. Jewett, J. Thompson, S. Tollefson, and P. F. Wright. 1997. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 175:807-813.
42. Rochat, S., H. Komada, and D. Kolakofsky. 1992. Loss of V protein expression in human parainfluenza virus type 1 is not a recent event. Virus Res. 24:137-144.
43. Schmidt, A. C., J. M. McAuliffe, B. R. Murphy, and P. L. Collins. 2001. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75:4594-4603.
44. Schmidt, A. C., D. R. Wenzke, J. M. McAuliffe, M. St. Claire, W. R. Elkins, B. R. Murphy, and P. L. Collins. 2002. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. 76:1089-1099.
45. Skiadopoulos, M. H., A. P. Durbin, J. M. Tatem, S. L. Wu, M. Paschalis, T. Tao, P. L. Collins, and B. R. Murphy. 1998. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72:1762-1768.
46. Skiadopoulos, M. H., S. Surman, J. M. Tatem, M. Paschalis, S. L. Wu, S. A. Udem, A. P. Durbin, P. L. Collins, and B. R. Murphy. 1999. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73:1374-1381.
47. Skiadopoulos, M. H., S. R. Surman, J. M. Riggs, P. L. Collins, and B. R. Murphy. 2001. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J. Virol. 75:10498-10504.
48. Skiadopoulos, M. H., S. R. Surman, J. M. Riggs, C. Orvell, P. L. Collins, and B. R. Murphy. 2002. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297:136-152.
49. Skiadopoulos, M. H., S. R. Surman, M. St. Claire, W. R. Elkins, P. L. Collins, and B. R. Murphy. 1999. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 260:125-135.
50. Skiadopoulos, M. H., T. Tao, S. R. Surman, P. L. Collins, and B. R. Murphy. 1999. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18:503-510.
51. Stokes, A., E. L. Tierney, C. M. Sarris, B. R. Murphy, and S. L. Hall. 1993. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3). Virus Res. 30:43-52.
52. Strahle, L., D. Garcin, P. Le Mercier, J. F. Schlaak, and D. Kolakofsky. 2003. Sendai virus targets inflammatory responses, as well as the interferon-induced antiviral state, in a multifaceted manner. J. Virol. 77:7903-7913.
53. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
54. van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7:719-724.